

CORRECTION

Open Access



# Correction: Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results

Andreas R. Gantenbein<sup>1\*</sup>, Reto Agosti<sup>2</sup>, Christian P. Kamm<sup>3,4</sup>, Gunther Landmann<sup>5</sup>, Niklaus Meier<sup>6</sup>, Gabriele Susanne Merki-Feld<sup>7</sup>, Jens A. Petersen<sup>8</sup>, Heiko Pohl<sup>9</sup>, Philippe Ryvlin<sup>10</sup>, Christoph J. Schankin<sup>3</sup>, Dragana Viceic<sup>11</sup>, Chiara Zecca<sup>12,13</sup>, Elisabeth Schäfer<sup>1</sup>, Ina Meyer<sup>14</sup> and Michael E. Arzt<sup>14</sup>

**Correction: J Headache Pain 23, 142 (2022)**  
<https://doi.org/10.1186/s10194-022-01515-8>

Following publication of the original article [1], the author group has identified an error in Fig. 1. The correct figure is given below.

The original article [1] has been corrected.

## Reference

1. Gantenbein AR, Agosti R, Kamm CP et al (2022) Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results. *J Headache Pain* 23:142. <https://doi.org/10.1186/s10194-022-01515-8>

## Author details

<sup>1</sup>Department of Neurology and Neurorehabilitation, ZURZACH Care, Bad Zurzach, Switzerland. <sup>2</sup>Kopfwehzentrum Hirslanden, Zurich, Switzerland. <sup>3</sup>Department of Neurology, Inselspital, University Hospital Bern and University of Bern, Bern, Switzerland. <sup>4</sup>Neurocentre, Luzerner Kantonsspital, Lucerne, Switzerland. <sup>5</sup>Center for Pain Medicine, Nottwil, Switzerland. <sup>6</sup>Department of Neurology, Spital Thun, Thun, Switzerland. <sup>7</sup>Department of Reproductive Endocrinology, University Hospital Zurich, Zurich, Switzerland. <sup>8</sup>Neurozentrum Bern, Bern, Switzerland. <sup>9</sup>Department of Neurology, University Hospital Zurich, Zurich, Switzerland. <sup>10</sup>Department of Clinical Neurosciences, CHUV, Lausanne, Switzerland. <sup>11</sup>Private Practice, Sion, Switzerland. <sup>12</sup>Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland. <sup>13</sup>Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland. <sup>14</sup>Novartis Pharma Schweiz AG, Rotkreuz, Switzerland.

Published online: 19 December 2022

The original article can be found online at <https://doi.org/10.1186/s10194-022-01515-8>.


\*Correspondence: [andreas.gantenbein@zurzachcare.ch](mailto:andreas.gantenbein@zurzachcare.ch)

<sup>1</sup> Department of Neurology and Neurorehabilitation, ZURZACH Care, Bad Zurzach, Switzerland

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.



**Fig. 1** Study design and visit schedule. mo: month; V: visit